The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Authors
Keywords
-
Journal
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-08-17
DOI
10.1002/hon.2667
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia
- (2018) Wen-Ting Wang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Improving CLL Vγ9Vδ2-T cell fitness for cellular therapy by ex vivo activation and ibrutinib
- (2018) Iris de Weerdt et al. BLOOD
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
- (2017) Qingsong Yin et al. JOURNAL OF IMMUNOLOGY
- Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
- (2017) K Kondo et al. LEUKEMIA
- Myeloid-Derived Suppressor Cells
- (2017) Dmitry I. Gabrilovich Cancer Immunology Research
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis
- (2016) G. Pavlasova et al. BLOOD
- Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
- (2016) Andrew Stiff et al. CANCER RESEARCH
- Regulatory T cells in cancer immunotherapy
- (2016) Atsushi Tanaka et al. CELL RESEARCH
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Targeting natural killer cells in cancer immunotherapy
- (2016) Camille Guillerey et al. NATURE IMMUNOLOGY
- Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
- (2016) Stefania Fiorcari et al. Oncotarget
- Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia
- (2016) Yi Miao et al. Oncotarget
- Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
- (2016) Vita Golubovskaya et al. Cancers
- Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
- (2015) C. U. Niemann et al. CLINICAL CANCER RESEARCH
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
- (2015) S-S Chen et al. LEUKEMIA
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
- (2014) H. E. Kohrt et al. BLOOD
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phenotype and functions of memory Tfh cells in human blood
- (2014) Nathalie Schmitt et al. TRENDS IN IMMUNOLOGY
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started